Nvidia Stock: China Could Be the Biggest Wild Card in NVDA Earnings

Nvidia heads into earnings with China still the key overhang: U.S. export curbs and China’s support for local chipmakers have sharply reduced Nvidia’s China AI chip sales. Although the U.S. has cleared some Chinese firms to buy Nvidia’s H200 chips, no shipments have occurred yet because local import approval is still pending. The stock could be sensitive to any update on China demand, even though Wall Street still rates NVDA a Strong Buy with a $282.35 average price target, implying 27% upside.

Analysis

The market is treating China as a binary headline risk, but the more important issue is earnings quality: even a modest reopening would be less about incremental revenue and more about restoring the durability of the AI capex narrative. If China stays constrained, NVDA’s multiple likely compresses because investors will have to underwrite growth from a narrower set of hyperscaler customers, which raises concentration risk and makes guidance less self-sustaining into the next 2-3 quarters.

The second-order winner is not necessarily a direct competitor so much as the local Chinese AI ecosystem. If U.S. access remains muddled, domestic accelerator, networking, and packaging players get a longer runway to secure design wins, while cloud buyers like BABA and JD can keep positioning themselves as beneficiaries of any incremental approval without actually needing shipments to occur immediately. That creates a classic “option value” setup in China internet: the stocks can re-rate on approval probability before revenue shows up.

Near term, the catalyst path is asymmetric. A clean approval would likely spark a sharp relief rally in NVDA because the street has already discounted partial bad news, but a continued stalemate matters more over months than days because it forces investors to model lower China contribution and potentially more aggressive pricing concessions elsewhere. The real tail risk is that the market extrapolates a one-time diplomatic thaw into a full normalization, when the structural export-control regime still leaves shipping, licensing, and enforcement as recurring friction points.

Consensus is probably missing that the stock does not need China to re-open meaningfully for the headline to move, but it does need China to stop being a recurring overhang for multiple expansion. That makes the setup less about absolute revenue upside and more about whether management can provide enough visibility to prevent another de-rating after earnings. If Huang sounds even slightly more constructive than expected, the stock can squeeze; if he is vague, the market may punish the guide more than the print.

Key Decisions for Investors

• Hold a short-dated NVDA call spread into earnings only if you expect a constructive China update; target a 2-3 week horizon with defined downside because implied volatility should remain elevated and a vague guide likely caps upside.
• For event-risk control, pair long BABA or JD against short NVDA over the next 1-2 months if you think the market will keep assigning China optionality to the buyers but continue discounting NVDA’s China monetization; this is a relative-value trade on approval timing, not fundamentals.
• If already long NVDA, trim into earnings and re-add only on a post-print pullback or a clear policy catalyst; the risk/reward is poor if management reiterates optimism without visible shipment timing.
• Watch for a tactical long in BABA after any explicit import-approval headline; these names can re-rate faster than NVDA because they benefit from optionality before revenue, with a favorable 1-3 month catalyst window.
• Avoid chasing the broader AI basket until the market gets either shipment confirmation or a cleaner multi-quarter guide; the overhang is more likely to compress multiples than expand them absent concrete China clarity.